The review emphasizes the importance of combined pharmacotherapy, such as fixed-dose lercanidipine/enalapril, in managing arterial hypertension according to the 2013 ESC/ESH guidelines.
Answers are grounded in this paper and cite their sources.
Supports combined antihypertensive regimens per 2013 guidelines; leaves open positioning amid subsequent evidence and updates.
The paper considers major changes in approaches to treating arterial hypertension in the context of the 2013 clinical guidelines on hypertension of the European Society of Cardiology/European Society of Arterial Hypertension. Prominence is given to a differentiated approach to combined pharmacotherapy, including the use of a fixed-dose lercanidipine/enalapril combination.
No takes yet. Share an insight, caveat, or question.
А. В. Родионов (2013) studied this question. Combined pharmacotherapy for arterial hypertension, including fixed-dose lercanidipine/enalapril, is emphasized as a prominent treatment approach in the 2013 ESC/ESH clinical guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: